Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of CY6463 when
administered to participants with stable schizophrenia who are on a stable antipsychotic
medication regimen